AUTL - Autolus Therapeutics

-

$undefined

N/A

(N/A)

Autolus Therapeutics NASDAQ:AUTL Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Location: Scale Space Building, White City, London, W12 7RZ, United Kingdom | Website: www.autolus.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

641.8M

Cash

705.9M

Avg Qtr Burn

-39.15M

Short % of Float

8.15%

Insider Ownership

18.03%

Institutional Own.

75.92%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
obe-cel (AUTO1) (CD19) Details
Acute lymphoblastic leukemia, Cancer, Blood cancer

Big Mover™

Susp. Mover™

PDUFA

Approval decision

AUTO4 Details
Peripheral T cell cancer

Phase 1/2

Update

Phase 1

Data readout

AUTO6NG Details
Solid tumor/s, Neuroblastoma

Phase 1

Data readout

AUTO1/22 (CD19 & CD22) Details
Acute lymphoblastic leukemia, Cancer, Leukemia

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Lymphoma, Leukemia, Cancer, Central nervous system illness, primary central nervous system lymphomas

Phase 1

Update

obe-cel (AUTO1) (CD19) Details
Lymphoma, Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Cancer, Leukemia

Phase 1

Update

AUTO5 Details
T-cell lymphoma

Phase 1

Initiation

AUTO3 (CD19, CD22) Details
Lymphoma, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued